HOHO Biotech, a member of the NVIDIA Inception Program , is the "Energy Company of Healthcare". We utilize proprietary HECC (Hydrogen-Enhanced Calcium Carbonate) technology to provide 24-hour stable molecular hydrogen release for sustained antioxidant protection and systemic immune modulation.

Our breakthrough innovation focuses on the universal drug adjuvant market. By incorporating just 17mg of our hydrogen powder into any medication, we can significantly eliminate drug side effects and increase therapeutic efficacy. 

This technology is validated by 30 scientific papers and years of large-scale clinical trials at Tri-Service General Hospital, a premier Medical Center in Taiwan. Based in Taipei, Tokyo, and Silicon Valley, HOHO Biotech aims to power the global healthcare and military supply chains, ensuring safer and more effective treatments for everyone.

HOHO Biotech’s core innovation is the Hydrogen-Enhanced Calcium Carbonate (HECC) technology, utilizing a proprietary Crystal-Molecule Interactive Storage mechanism. Unlike traditional hydrogen products, HECC provides stable molecular hydrogen release for up to 24 hours, ensuring continuous antioxidant protection and systemic immune modulation.

A transformative application is our universal drug adjuvant. By integrating just 17mg of HECC powder as a carrier, medications can eliminate side effects while enhancing therapeutic efficacy. This "Healthcare Energy" solution is validated by 30 scientific publications and extensive clinical trials at Tri-Service General Hospital, a premier Medical Center. Leveraging AI-driven formulation through the NVIDIA Inception Program, HOHO Biotech optimizes molecule-drug matching to revolutionize pharmaceutical standards and military mission-readiness.

1. Targeting Potential Customers:

 Target customers are major U.S. pharmaceutical companies, top-tier Medical Centers, and defense agencies (Military Rations) in CA, MD, and MA. We seek partners to integrate our 17mg HECC adjuvant into drug formulations to eliminate side effects and enhance mission-readiness globally.

2. Fundraising Requirements (Target Investor Profile):

Targeting Pre-A/Series A Venture Capitalists and strategic partners in Biotech, MedTech, and Defense sectors across CA, MA, and MD. We seek $1M–$5M to scale our HECC adjuvant technology, focusing on FDA compliance and pharmaceutical partnerships to eliminate drug side effects.

3. U.S. Operation Layout & Support Needed:

HOHO Biotech plans a U.S. subsidiary in CA/MD, focusing on site selection and hiring clinical experts. We seek assistance with tax/legal regulations, FDA compliance for HECC adjuvant, and partnerships with Medical Centers to scale our powder technology for eliminating drug side effects.

4. Strategic Medical & Academic Partners:

Presidents & Department Heads of Rheumatology/Immunology: We aim to engage with high-level leaders (Professors/Directors) at Johns Hopkins Medicine, Stanford Medicine, and Mass General. Our goal is to establish Clinical Trial Collaborations where HOHO Biotech provides HECC capsules, and the partner institution provides funding, clinical staff, and facilities.

Hospital Systems for "Self-paid Prescriptions": We seek to replicate our successful Taiwan Medical Center model by listing HECC capsules as "In-hospital Self-paid Nutritional Prescriptions" for chronic autoimmune patients (RA/SLE).

5. Pharmaceutical & Defense Partners:

AbbVie, Janssen, & Pfizer: To integrate our 17mg HECC adjuvant into their existing immunology drug portfolios.

Defense Health Agency (DHA): To incorporate HECC into Military Rations for the "Special Forces" radiation and toxicant protection programs.

6. Venture Capital:

NVIDIA NVentures & Khosla Ventures: Targeting VCs that lead in AI-driven material science and clinical breakthroughs.